| Authors: |
Hewitt E; Beacon: for Rare Disease, Cambridge, UK., Bouche G; The Anticancer Fund, Meise, Belgium., Alencar AC; Rising Tide Foundation for Clinical Cancer Research, Schaffhausen, Switzerland., Bigelsen SJ; Patient Advocate, Department of Allergy, Asthma and Immunology, Rutgers New Jersey Medical School, Newark, NJ, USA., Radu R; Medicines for Europe, Brussels, Belgium., Stoyanova-Beninska V; College ter Beoordeling van Geneesmiddelen, Utrecht, the Netherlands., Carrato A; Department of Medical Oncology, Alcalá University, Instituto Ramón Y Cajal de Investigación Sanitaria (IRYCIS), Centro de Investigación Biomédica En Red de Cáncer (CIBERONC), Ramon Y Cajal University Hospital, Madrid, Spain.; Pancreatic Cancer Europe, Brussels, Belgium., Valsecchi F; Fondazione Nadia Valsecchi, Brescia, Italy., Soler Cantón A; EATRIS ERIC, European Infrastructure for Translational Medicine, Amsterdam, the Netherlands., van der Meer HG; ZonMw, The Hague, the Netherlands., García Bermejo ML; Biomarkers and Therapeutic Targets Group, Instituto Ramón Y Cajal de Investigación Sanitaria (IRYCIS), Ramon Y Cajal University Hospital, Madrid, Spain., Budillon A; Scientific Directorate, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy., Cardone L; Institute of BiOChemistry and Cell Biology (IBBC), CNR c/o Campus Internazionale 'a.buzzati-Traverso', Monterotondo Scalo Roma (Rome), Italy.; Department of Tumour Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Rooman I; The Anticancer Fund, Meise, Belgium.; Translational Oncology Research Center (TORC), Laboratory of Medical and Molecular Oncology, (LMMO) Vrije Universiteit Brussel, Brussels, Belgium., Platteeuw H; Galenicap, Brussels, Belgium., Baijet J; EURORDIS - Rare Diseases Europe, Paris, France., Fuchs C; EURORDIS - Rare Diseases Europe, Paris, France. |
